ConductScience.org, home

Comparison · NCT00013611-33f19b1b

Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Serious Disease Progression Events or Death

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Serious Disease Progression Events or Death. Trial comparisons, record NCT00013611-33f19b1b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00013611-33f19b1b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02240.01440.0347wilson
Risk in group 20.03310.0230.0474wilson
Risk difference, group 1 minus group 2-0.0107-0.02710.0052newcombe hybrid score
Risk ratio, group 1 over group 20.6760.3811.2log
Odds ratio, group 1 over group 20.6690.3711.21log
Number needed to treat, for one fewer participant with the outcome on Proleukin Plus Antiretroviral Therapy than on Antiretroviral Therapy Only93.3from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Proleukin Plus Antiretroviral Therapy19849OG000
Group 2Antiretroviral Therapy Only28846OG001

Outcome

Type
SECONDARY
Title
New or Recurrent Serious Disease Progression Events or Death
Description
Number of participants with fatal or non-fatal serious AIDS-related opportunistic disease.~A serious disease progression event is one of the following: progressive multifocal leukoencephalopathy (PML), lymphoma, Kaposi's sarcoma (visceral), AIDS dementia complex (ADC) stage II or higher, toxoplasmosis, histoplasmosis (systemic), cryptococcosis (systemic), disseminated Mycobacterium avium complex (MAC) disease, wasting syndrome, and cytomegalovirus (CMV) disease.
Time frame
From randomization to date last known to be alive or November 15, 2008, whichever is earlier
Population

Source ClinicalTrials.gov

Trial

Title
Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
NCT number
NCT00013611
Phases
PHASE3
Conditions
HIV Infection
Interventions
Proleukin
Lead sponsor
University of Minnesota
Results first posted
2010-12-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00013611-33f19b1b